Ellagic Acid Exerts Beneficial Effects on Hyperuricemia by Inhibiting Xanthine Oxidase and NLRP3 Inflammasome Activation

• DOI: 10.1021/acs.jafc.1c05239
• Publication Date: 2021-10-21T11:51:30Z
• Authors: Ze-Rui Sun; Hua-Rong Liu; Di Hu; Mao-Si Fan; Ming-Yue Wang; Meng-Fei An; Yun-Li Zhao; Ze-Min Xiang; Jun Sheng
• Keywords: Ellagic Acid

Hyperuricemia is a metabolic disease caused by impaired uric acid (UA) metabolism. Ellagic (EA) natural small-molecule polyphenolic compound with known antioxidative and anti-inflammatory properties. Here, we evaluated the regulatory effects of EA on hyperuricemia explored underlying mechanisms. We found that an effective xanthine oxidase (XOD) inhibitor (IC50 = 165.6 μmol/L) superoxide anion scavenger 27.66 μmol/L). (5 10 treatment significantly dose-dependently reduced UA levels in L-O2 cells; meanwhile, intraperitoneal administration (50 100 mg/kg) also serum XOD activity hyperuricemic mice markedly improved their liver kidney histopathology. degree foot edema inhibited expression NLPR3 pathway-related proteins tissue monosodium urate (MSU)-treated mice. The effect was observed lipopolysaccharide-stimulated RAW-264.7 cells. Furthermore, expressions NLRP3 (TLR4, p-p65, caspase-1, TNF-α, IL-18) vitro vivo. Our results indicated exerts ameliorative experimental via regulating signaling pathway represents promising therapeutic option for management hyperuricemia.